Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Janku F. et al, (2024), Cancers, 16

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

Dixon-Zegeye M. et al, (2024), Trials, 25

UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies.

Lythgoe MP. et al, (2023), Lancet Oncol, 24, 963 - 966

Early phase antitumour clinical trials and palliative medicine.

Virani F. et al, (2023), BMJ Support Palliat Care

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.

Luke JJ. et al, (2023), Br J Cancer

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.

Kristeleit R. et al, (2023), British journal of cancer

From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit

Lythgoe MP. et al, (2023), The Lancet Oncology, 24, e150 - e160

Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Data from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Data from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Supplementary Data from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Supplementary Information from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Supplementary Information from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Table S2 from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Table S2 from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Load More

1
2
3
4
5
6
7
...
»